FMP

FMP

Enter

SYK - Stryker Corporation

photo-url-https://images.financialmodelingprep.com/symbol/SYK.png

Stryker Corporation

SYK

NYSE

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

357.11 USD

8.99 (2.52%)

Operating Data

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

14.35B

17.11B

18.45B

20.5B

22.59B

25.33B

28.39B

31.83B

35.68B

39.99B

Revenue %

-

19.21

7.84

11.11

10.23

12.1

12.1

12.1

12.1

Ebitda

3.75B

4.65B

4.54B

4.93B

5.72B

6.45B

7.23B

8.1B

9.08B

10.18B

Ebitda %

26.17

27.16

24.59

24.07

25.3

25.46

25.46

25.46

25.46

Ebit

2.94B

3.66B

3.54B

3.91B

4.67B

5.1B

5.72B

6.41B

7.19B

8.06B

Ebit %

20.51

21.37

19.18

19.06

20.65

20.15

20.15

20.15

20.15

Depreciation

812M

990M

998M

1.03B

1.05B

1.34B

1.51B

1.69B

1.89B

2.12B

Depreciation %

5.66

5.79

5.41

5.02

4.65

5.3

5.3

5.3

5.3

Balance Sheet

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Total Cash

3.02B

3.02B

1.93B

3.05B

4.4B

4.23B

4.74B

5.32B

5.96B

6.68B

Total Cash %

21.07

17.65

10.45

14.89

19.48

16.71

16.71

16.71

16.71

Receivables

2.7B

3.02B

3.56B

3.77B

3.99B

4.65B

5.21B

5.84B

6.55B

7.34B

Receivables %

18.82

17.66

19.32

18.37

17.65

18.36

18.36

18.36

18.36

Inventories

3.49B

3.31B

4B

4.84B

4.77B

5.58B

6.25B

7.01B

7.86B

8.81B

Inventories %

24.35

19.37

21.65

23.63

21.13

22.03

22.03

22.03

22.03

Payable

810M

1.13B

1.41B

1.52B

1.68B

1.76B

1.97B

2.21B

2.48B

2.78B

Payable %

5.64

6.6

7.66

7.4

7.43

6.95

6.95

6.95

6.95

Cap Ex

-487M

-525M

-588M

-575M

-755M

-800.17M

-896.96M

-1.01B

-1.13B

-1.26B

Cap Ex %

-3.39

-3.07

-3.19

-2.81

-3.34

-3.16

-3.16

-3.16

-3.16

Weighted Average Cost Of Capital

Price

357.11

Beta

Diluted Shares Outstanding

385.6M

Costof Debt

4

Tax Rate

After Tax Cost Of Debt

3.43

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

1.41B

Total Equity

137.7B

Total Capital

139.11B

Debt Weighting

1.01

Equity Weighting

98.99

Wacc

8.37

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

14.35B

17.11B

18.45B

20.5B

22.59B

25.33B

28.39B

31.83B

35.68B

39.99B

Ebitda

3.75B

4.65B

4.54B

4.93B

5.72B

6.45B

7.23B

8.1B

9.08B

10.18B

Ebit

2.94B

3.66B

3.54B

3.91B

4.67B

5.1B

5.72B

6.41B

7.19B

8.06B

Tax Rate

14.29

14.29

14.29

14.29

14.29

14.29

14.29

14.29

14.29

14.29

Ebiat

2.41B

3.2B

3.11B

3.37B

4B

4.38B

4.91B

5.5B

6.17B

6.92B

Depreciation

812M

990M

998M

1.03B

1.05B

1.34B

1.51B

1.69B

1.89B

2.12B

Receivables

2.7B

3.02B

3.56B

3.77B

3.99B

4.65B

5.21B

5.84B

6.55B

7.34B

Inventories

3.49B

3.31B

4B

4.84B

4.77B

5.58B

6.25B

7.01B

7.86B

8.81B

Payable

810M

1.13B

1.41B

1.52B

1.68B

1.76B

1.97B

2.21B

2.48B

2.78B

Cap Ex

-487M

-525M

-588M

-575M

-755M

-800.17M

-896.96M

-1.01B

-1.13B

-1.26B

Ufcf

-2.65B

3.84B

2.58B

2.87B

4.3B

3.53B

4.49B

5.04B

5.65B

6.33B

Wacc

8.37

8.37

8.37

8.37

8.37

Pv Ufcf

3.26B

3.83B

3.96B

4.09B

4.23B

Sum Pv Ufcf

19.37B

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

8.37

Free Cash Flow T1

6.58B

Terminal Value

150.56B

Present Terminal Value

100.72B

Intrinsic Value

Enterprise Value

120.09B

Net Debt

-2.24B

Equity Value

122.33B

Diluted Shares Outstanding

385.6M

Equity Value Per Share

317.26

Projected DCF

317.26 -0.126%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep